CIK 0001022079 · Large accelerated filer
QUEST DIAGNOSTICS INC
Sign in to watch- Ticker
- DGX
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 161387862
- Phone
- 9735202700
- Business address
- 500 PLAZA DRIVE, SECAUCUS, NJ, 07094
- Former names
- CORNING CLINICAL LABORATORIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,730,307
- in 5 filings, $16.7M under 10b5-1 plans
Net −$16,730,307. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- PREVOZNIK MICHAEL E −$5.5M SVP & General Counsel sold 38% of stake
- Doherty Catherine T. −$5.5M Executive Vice President sold 24% of stake
- Plewman Patrick −$3.0M SVP for Diagnostic Services sold 44% of stake
- Davis J. E. −$2.4M CEO and President sold 8% of stake
- PFEIFFER GARY M −$292K Director sold 4% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-13 | Doherty Catherine T. EVP, Regional Businesses | Sale 10b5-1 | −10,122 | $206.37 | $2.1M | 73,538 |
| 2026-02-13 | Doherty Catherine T. EVP, Regional Businesses | Sale 10b5-1 | −3,500 | $207.08 | $725K | 70,038 |
| 2026-02-13 | Doherty Catherine T. EVP, Regional Businesses | Sale 10b5-1 | −1,619 | $208.21 | $337K | 68,419 |
| 2026-02-13 | Doherty Catherine T. EVP, Regional Businesses | Sale 10b5-1 | −351 | $209.10 | $73K | 68,068 |
| 2026-02-13 | Doherty Catherine T. EVP, Regional Businesses | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −26,165 | $112.17 | $2.9M | 0 |
| 2026-02-10 | Plewman Patrick SVP for Diagnostic Services | Option exercise 10b5-1 | +5,662 | $121.81 | $690K | 21,043 |
| 2026-02-10 | Plewman Patrick SVP for Diagnostic Services | Sale 10b5-1 | −5,662 | $204.00 | $1.2M | 15,381 |
| 2026-02-10 | Plewman Patrick SVP for Diagnostic Services | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −5,662 | $121.81 | $690K | 0 |
| 2026-01-28 | DELANEY MARK E SVP & Chief Commercial Officer | Other acquisition | +15 | $183.51 | $3K | 8,696 |
| 2026-01-28 | KUPPUSAMY KARTHIK SVP, Clinical Solutions | Other acquisition | +16 | $183.52 | $3K | 10,065 |
| 2026-01-28 | SAMAD SAM Executive Vice President & CFO | Grant or award | +69 | $183.51 | $13K | 27,910 |
| 2026-01-28 | Gregg Vicky B Director | Other acquisition | +67 | $183.51 | $12K | 17,104 |
| 2026-01-28 | CARTER ROBERT B Director | Other acquisition | +6 | $183.51 | $1K | 2,704 |
| 2026-01-28 | Lassiter Wright III Director | Other acquisition | +7 | $183.51 | $1K | 9,057 |
| 2026-01-28 | Plewman Patrick SVP for Diagnostic Services | Grant or award 10b5-1 | +48 | $183.51 | $9K | 15,381 |
| 2025-11-25 | Davis J. E. CEO and President | Option exercise 10b5-1 | +55,093 | $95.80 | $5.3M | 175,573 |
| 2025-11-25 | Davis J. E. CEO and President | Sale 10b5-1 | −9,342 | $191.59 | $1.8M | 166,231 |
| 2025-11-25 | Davis J. E. CEO and President | Sale 10b5-1 | −41,004 | $192.27 | $7.9M | 125,227 |
| 2025-11-25 | Davis J. E. CEO and President | Sale 10b5-1 | −4,747 | $192.97 | $916K | 120,480 |
| 2025-11-25 | Davis J. E. CEO and President | Option exercise · Non-Qualifed Stock Option (right to buy) 10b5-1 | −55,093 | $95.80 | $5.3M | 0 |
Page 8 of 21 · 409 trades